PEPTIQORE™
Quality DatabaseSemaglutide

PEPTIQORE QUALITY RECORD

Semaglutide Quality Intelligence

Semaglutide is a GLP-1 receptor agonist peptide with a C18 fatty diacid side chain attached via a mini-PEG linker and a gamma-glutamic acid spacer to lysine at position 26. The fatty acid modification enables albumin binding and extends the plasma half-life to approximately one week, enabling once-weekly dosing.

GLP-1 Receptor AgonistType 2 diabetes mellitus; obesity (higher dose formulation)Partial DataReference Material AvailableCustom Synthesis AvailableCustom Analysis Available

QUALITY RECORD

PQ-PEP-000001

RECORD TYPE

Therapeutic Peptide

PEPTIQORE ID

PQ-PEP-000001

CAS NUMBER

910463-68-2

MOLECULAR WEIGHT

4113.6 Da

AMINO ACIDS

31

RECORD VERSION

1.0

RECORD COMPLETENESS

IdentityComplete
Impurity DataPartial
Reference MaterialsPartial
Analytical DataPartial
MethodsPartial
LiteratureComplete

IDENTITY

Semaglutide Identity

Semaglutide is a GLP-1 receptor agonist peptide with a C18 fatty diacid side chain attached via a mini-PEG linker and a gamma-glutamic acid spacer to lysine at position 26. The fatty acid modification enables albumin binding and extends the plasma half-life to approximately one week, enabling once-weekly dosing.

MOLECULAR FORMULA

C₁₈₇H₂₉₁N₄₅O₅₉

CALCULATED MW

4113.6 Da

CAS NUMBER

910463-68-2

AMINO ACID COUNT

31

QUALITY RISKS

Relevant Quality Pathways

Based on published literature and regulatory data. Not all pathways necessarily occur in every batch.

Oxidation

Met oxidation is a relevant degradation pathway

Relevant

Deamidation

Asn deamidation under stressed conditions

Relevant

Hydrolysis

Fatty acid side chain hydrolysis

Relevant

Isomerization

Asp isomerization

Relevant

Aggregation

Aggregation-related species

Not reported

QUALITY MAP

Semaglutide Quality Map

Relevant quality pathways and impurity categories. Data completeness varies by category.

Process-Related Impurities

Synthesis, modification, coupling, cleavage or purification

  • Des-fatty acid impurity (loss of C18 side chain)
  • Incompletely modified lysine variants
  • Linker-related impurities
  • Regioisomeric acylation variants

Relevant quality pathways — not all necessarily present in every batch.

Sequence-Related Impurities

Deletion, insertion, truncation and epimeric variants

  • Deletion variants (single amino acid deletions)
  • Truncated sequences (N- or C-terminal truncations)
  • Epimeric variants (D-amino acid incorporation)
  • Incorrect sequence variants

Only list specific impurities when supported by credible source or PeptiQore experimental record.

Degradation-Related Impurities

Oxidation, deamidation, hydrolysis and other degradation pathways

  • Met oxidation products
  • Asn deamidation products
  • Fatty acid side chain hydrolysis products
  • Asp isomerization products

Relevant quality pathways based on published literature and regulatory data.

QUALITY GRAPH

Semaglutide Knowledge Graph

Connected quality knowledge — not a product catalog.

QUALITY INTELLIGENCE

Analyze Semaglutide Quality Risk

Use PeptiQore Intelligence to explore degradation pathways, interpret mass shifts, investigate unknown peaks and review impurity strategy for semaglutide.

COMMERCIAL SUPPORT

Semaglutide Quality Support

Request Reference Material

Semaglutide parent or impurity reference material for analytical use.

Request Reference Material

Request Custom Synthesis

Custom synthesis of semaglutide-related impurities not in the standard catalog.

Request Custom Synthesis

Investigate Unknown Peak

Unexpected chromatographic peak in your semaglutide sample requiring investigation.

Investigate Unknown Peak

SOURCES & EVIDENCE

REGULATORYPEER-REVIEWEDCOMPENDIALPEPTIQORE EXPERIMENTAL

PeptiQore provides scientific information for professional laboratory, development and quality-control use. Public database content may include literature-derived, regulatory, experimental and computational information. Users should evaluate source and evidence status before applying information to regulated decisions.